Key Highlights
● Attention instead stems from the company's steady, if modest, operating cadence.
● Founded in 1980 and based in New Jersey, Integrated BioPharma manufactures and distributes vitamins, nutritional supplements and herbal products, largely through contract Manufacturing for distributors, marketers and healthcare providers.
● Shares traded in the high-teens of a cent, giving Integrated BioPharma a market Capitalization of only around $5 to $6 million.
● The next concrete event on the calendar is the company's fiscal year-end results, expected in late September 2026, which will show full-year Revenue and margins and how the March-quarter softness played out.
Company and Latest Development
Founded in 1980 and based in New Jersey, Integrated BioPharma (OTC:INBP) manufactures and distributes vitamins, nutritional supplements and herbal products, largely through contract manufacturing for distributors, marketers and healthcare providers. Its core operating unit is Wholly Owned Subsidiary Manhattan Drug Company. The most recent verified corporate development came on 20 August 2026, when the company announced that Manhattan Drug Company had appointed Michael Richtmyer as Head of Operations, citing more than 35 years of Leadership across manufacturing, Supply chain and quality. That followed its fiscal-quarter report for the period ended 31 March 2026, released on 8 May 2026, which showed quarterly revenue of about $10.1 million.
What Is Driving Attention Around INBP?
Attention instead stems from the company's steady, if modest, operating cadence. Recent quarterly revenue has run in the roughly $10 million to $13 million range per quarter, reflecting an operating Business rather than a speculative concept. As a nutraceutical contract manufacturer, INBP is more a consumer-staples supplier than a clinical-stage biotech, a distinction that shapes how its results should be read.
Key Numbers and Company Position
Shares traded in the high-teens of a cent, giving Integrated BioPharma a market capitalization of only around $5 to $6 million. For its fiscal year ended 30 June 2025, the company reported revenue of about $54 million, up single digits year over year, and returned to modest positive net income. More recent quarters have shown revenue easing on a trailing basis, and profitability has been thin. Reported quarterly revenue was roughly $12.7 million for the period ended 30 September 2025, $11.3 million for 31 December 2025, and $10.1 million for 31 March 2026. The company trades on the OTCQX marketplace rather than a national exchange.
What Could Come Next?
The next concrete event on the calendar is the company's fiscal year-end results, expected in late September 2026, which will show full-year revenue and margins and how the March-quarter softness played out. Investors may also watch for operational effects from the new Manhattan Drug Company leadership, new or renewed contract-manufacturing agreements, and any commentary on customer demand. Given the small float, even minor operating news can move the shares.
Risks to Watch
Key risks include heavy customer concentration, a recurring feature of contract manufacturing, which leaves revenue exposed to the loss of a major client. Thin profitability, input-cost pressure and competitive dynamics in the crowded supplements market are ongoing concerns. As an OTCQX-listed micro-cap trading below a dollar, the stock also carries liquidity risk, wider spreads and limited analyst coverage, all of which can amplify volatility.
Integrated BioPharma, Inc's Near-Term Catalysts Now Matter
Integrated BioPharma is a small nutraceutical manufacturer whose shares have stagnated even as the underlying business keeps producing tens of millions in annual revenue. The quiet price action reflects its micro-cap, OTCQX status rather than any specific setback. Investors interested in INBP may be watching the upcoming fiscal year-end report, the impact of new operational leadership at Manhattan Drug Company, and any shifts in customer Demand as the developments most likely to shape sentiment.






Please wait processing your request...